Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy Combined With Pembrolizumab in Advanced Brain Cancer
NCT06640582Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GC101 TIL + pembrolizumab in brain cancer, glioma and meningioma, sponsored by Essen BioTech. Primary endpoint: Adverse Events at 6 months. Started Oct 2024; status: recruiting.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
brain cancergliomameningioma
Beyond the preview
Go deeper on NCT06640582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640582.